Health ProductsDear Healthcare Professional Letter

EnTrust VR/DR/AT Implantable Cardioverter Defibrillators (ICDs) - Urgent - Medical Device Correction - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Medical Device
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Medtronic of Canada, Ltd. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories



Health Canada Endorsed Important Safety Information on EnTrust VR/DR/AT Implantable Cardioverter Defibrillators (ICDs)

March 6, 2012

Dear Health Care Professional:

Subject: URGENT: MEDICAL DEVICE CORRECTION EnTrust VR/DR/AT Implantable Cardioverter Defibrillators (ICDs)

Medtronic is advising you that a small percentage of EnTrust ICDs may not meet expected longevity or provide at least three months of device operation between the Elective Replacement Indicator (ERI) and End of Life (EOL) due to a more-rapid-than-expected drop in battery voltage.  An estimated 39,000 EnTrust ICDs are currently implanted worldwide.  No patient deaths or serious injuries have been reported as a result of this issue.   Medtronic is also communicating this information to Health Canada.

The reported events have involved a drop in battery voltage from ~3.0 V to ERI (2.61 V) over a time period ranging from approximately one week to six months.  All reported events have occurred at least 30 months after implant. Medtronic has confirmed nine reports of charge circuit time out during automatic capacitor formations and one report of loss of pacing, all occurring between ERI and device explant.  Although the potential exists for loss of high voltage therapy between ERI and device explant, this has not been reported to date.

Medtronic has identified the cause of these occurrences to be an internal battery short that develops as the battery capacity is consumed.  As of February 20, 2012, reported events for this issue include 44 (0.15%) single chamber (VR) devices and 16 (0.04%) dual chamber (DR/AT) devices. Four of these reports originated in Canada, 2 for single chamber (VR) devices and 2 for dual chamber (DR/AT) devices. The current reported failure rate is low; however, there is uncertainty in projecting future performance.  We are committed to providing you with ongoing updates in our Product Performance Report.

After consultation with Medtronic's Independent Physician Quality Panel, Medtronic offers the following patient management recommendations:

  • Physicians should continue routine follow-up sessions at least every three months in accordance with product labeling. 
  • Physicians should program the audible patient alerts for "Low Battery Voltage ERI" and "Excessive Charge Time EOL" to ON.
  • Physicians should replace devices promptly after they reach ERI if the decline in voltage is more rapid than expected.
  • Prophylactic replacement of EnTrust ICDs is not recommended.

A list of specific model and serial numbers of affected devices has been provided to implant centers and/or follow-up clinics in accordance with our device registration records.  We regret any difficulties this may cause you and your patients.  If you have any questions or if we can be of assistance, please contact your local Medtronic Representative or Medtronic Technical Services at 800-723-4636.

Managing marketed health product-related adverse incidents depends on health care professionals and consumers reporting them.  Reporting rates determined on the basis of spontaneously reported post-marketing adverse incidents are generally presumed to underestimate the risks associated with health product treatments.  Any incident or other serious or unexpected adverse incidents involving products manufactured and/or distributed by Medtronic should be reported to Medtronic, or to Health Canada at the following address:

Medtronic of Canada, Ltd.
99 Hereford St.
Brampton, Ontario
L6Y 0R3
Telephone: 1-800-268-5346

Any suspected adverse incident can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Telephone: The Inspectorate Hotline 1-800-267-9675

The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada Web site.

For other medical device inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

To change your mailing address or fax number, contact the Market Authorization Holder (Industry).

Sincerely,

original signed by

Jon Olsen, Senior Director, Cardiac & Vascular Group
Medtronic of Canada Ltd.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime